Iasocholine

Fluorocholine (18F) chloride, the active ingredient in Iasocholine, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used for PET imaging of prostate cancer in adult patients.

GNH USA supplies Iasocholine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Iasocholine is employed in diagnostic imaging that targets choline metabolism, primarily for prostate cancer assessment.

Prostate cancer: enables detection and staging of primary disease through PET imaging. Prostate cancer recurrence: helps evaluate biochemical recurrence when PSA levels rise. Metastatic disease evaluation: improves identification of distant lesions in advanced prostate cancer.

Adverse reactions are generally mild but can occur after intravenous administration.

Common Side Effects: - Injection site pain or erythema - Transient nausea or vomiting - Mild headache - Flushing or warmth sensation - Dizziness or light‑headedness - Temporary increase in blood pressure

Serious or Rare Side Effects: - Allergic reaction including urticaria or angioedema - Anaphylaxis requiring emergency treatment - Severe hypotension or cardiovascular collapse - Radiation‑induced skin injury at the injection site - Unexpected organ toxicity in patients with compromised renal function - Rare neurological events such as seizures

Prior to use, clinicians should assess patient history and ensure appropriate handling of the radiopharmaceutical. - Pregnancy status: avoid use unless clearly needed, as fetal radiation exposure is unknown. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: consider dose adjustment or alternative imaging if severe. - Concomitant radiotracers: avoid simultaneous administration of other PET agents. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluorocholine may interact with substances that affect choline metabolism or alter biodistribution.

Major Interactions (Avoid): - High‑dose choline supplements: can compete for transporter uptake. - Concurrent administration of other radiotracers: may cause overlapping radiation exposure. - Strong CYP450 inducers: may alter clearance of co‑administered drugs.

Moderate Interactions (Monitor Closely): - Statins: may modestly reduce tracer uptake in hepatic tissue. - Anticholinergic agents: could affect choline transporter activity. - Diuretics: may influence renal excretion of the tracer.